Wall Street Zen lowered shares of bioAffinity Technologies (NASDAQ:BIAF – Free Report) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Friday, October 16th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has a consensus rating of “Sell”.
Check Out Our Latest Report on BIAF
bioAffinity Technologies Stock Performance
Shares of BIAF stock traded down $0.14 on Friday, reaching $2.20. The stock had a trading volume of 51,160 shares, compared to its average volume of 94,390. The company has a quick ratio of 1.41, a current ratio of 1.51 and a debt-to-equity ratio of 0.13. The firm’s 50-day moving average is $5.36 and its two-hundred day moving average is $18.25. The firm has a market capitalization of $4.00 million, a price-to-earnings ratio of -0.05 and a beta of -1.04. bioAffinity Technologies has a 12 month low of $2.17 and a 12 month high of $80.70.
bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported ($5.89) EPS for the quarter, topping analysts’ consensus estimates of ($31.50) by $25.61. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.91 million. bioAffinity Technologies had a negative return on equity of 293.44% and a negative net margin of 278.90%.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc. is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other serious diseases. The company’s platform uses porphyrin-based compounds designed to selectively identify or target abnormal cells, with the goal of supporting earlier disease detection and more precise treatment. Its lead diagnostic product, CyPath Lung, is an investigational, noninvasive urine test intended to aid in the detection of lung cancer. The test uses an inhaled porphyrin compound that can bind to cancer cells in the lungs; the resulting material is collected in urine and analyzed using laboratory methods.
Further Reading
- Five stocks we like better than bioAffinity Technologies
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
